A company with extensive experience of generic pharmaceuticals, Medis offers a broad portfolio of products and intellectual property to other pharmaceutical companies. We have a proven track record in securing regulatory approval prior to patent expiries, and have obtained marketing authorisations in over 50 countries to date.

Medis draws on the development and manufacturing capabilities of its parent company, Actavis, whose R&D specialists maintain a strong development pipeline.

We provide generic pharmaceutical products for human use,  mainly in the form of tablets, capsules and injections. Now featured in our comprehensive portfolio is a growing range of specialist oncology products.